STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co., Inc. - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.

Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.

Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.

The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.

From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.

News

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results

Rhea-AI Summary
Merck (MRK) announced its fourth-quarter and full-year sales for 2023, reflecting sustained growth across oncology and vaccines. The worldwide sales for the fourth quarter were $14.6 billion, showing a 6% increase from the fourth quarter of 2022. For the full year, the sales were $60.1 billion, an increase of 1% from 2022. KEYTRUDA sales grew by 19% to $25.0 billion, and GARDASIL/GARDASIL 9 sales grew by 29% to $8.9 billion. However, LAGEVRIO sales declined by 75% to $1.4 billion. Merck also obtained FDA priority review of biologics license applications for V116, an investigational pneumococcal conjugate vaccine, and Patritumab Deruxtecan. The company initiated more than 20 phase 3 study starts and augmented its pipeline through acquisitions and collaboration agreements. The full-year 2024 financial outlook anticipates worldwide sales to be between $62.7 billion and $64.2 billion, with non-GAAP EPS expected to be between $8.44 and $8.59.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
earnings
-
News

The Wall Street Journal Names Merck Among Top 10 Best-Managed Companies

Rhea-AI Summary
Our company, MRK, has been recognized for its strong performance and leadership, ranking No. 10 on The Wall Street Journal's list of the 250 best-managed publicly traded U.S. companies in 2023. The company advanced 78 places from the previous year, showcasing its strategic focus, innovation, and unwavering commitment to saving and improving lives. MRK also secured the No. 1 spot on Newsweek's 2024 list of America's Most Responsible Companies, highlighting its dedication to corporate citizenship and responsible operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
News

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

Rhea-AI Summary
Merck (MRK) announced positive results from the Phase 3 KEYNOTE-564 trial, demonstrating a 38% improvement in overall survival (OS) with KEYTRUDA compared to placebo in patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following surgery. The OS rate at 48 months was 91.2% for KEYTRUDA patients compared to 86.0% for placebo patients. The trial also met its primary endpoint of disease-free survival (DFS) by reducing the risk of disease recurrence or death by 32%. The safety profile of KEYTRUDA was consistent with previous studies, with treatment-related adverse events occurring in 79.1% of KEYTRUDA patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Unexpected Inspiration for More Sustainable Drug Development at Merck

Rhea-AI Summary
Merck scientist François Lévesque shares the amazing story of how creativity and Green Chemistry made drug development more sustainable. The inspiration for a greener world can come from unexpected places, as seen in this surprising journey from the pet store to sustainable drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
News

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery

Rhea-AI Summary
Merck announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating KEYTRUDA for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma. KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS), reducing the risk of disease recurrence or death by 31% versus observation after surgery. Median DFS was 29.0 months for KEYTRUDA and 14.0 months for observation. Overall survival (OS) did not reach statistical significance at this interim analysis. KEYTRUDA is a potential new adjuvant option for patients with resectable muscle-invasive bladder cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
News

Merck Announces Second-Quarter 2024 Dividend

Rhea-AI Summary
Merck (NYSE: MRK) has declared a quarterly dividend of $0.77 per share of the company’s common stock for the second quarter of 2024, with payment to be made on April 5, 2024. This announcement reflects the company's commitment to providing returns to its shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
dividends
News

Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1

Rhea-AI Summary
Merck (MRK) will hold its Q4 and full-year 2023 sales and earnings conference call on Feb. 1, providing an overview of performance and outlook for 2024. The call will be accessible via live audio webcast and a replay will be available on the company's website. Institutional investors, analysts, journalists, and the general public can join the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
earnings
-
News

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Rhea-AI Summary
Merck's anti-PD-1 therapy, KEYTRUDA, has been approved by the FDA in combination with chemoradiotherapy for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer. The approval is based on data from the Phase 3 KEYNOTE-A18 trial, which showed a 41% reduction in the risk of disease progression or death compared to placebo plus CRT. This marks the third indication for KEYTRUDA in cervical cancer and the 39th indication for KEYTRUDA in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
fda approval
-
News

Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

Rhea-AI Summary
Merck (MRK) to Acquire Harpoon Therapeutics (HARP) for $680 Million, Adding HPN328 to Its Oncology Pipeline
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
acquisition
News

Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline

Rhea-AI Summary
Merck (MRK) initiates pivotal Phase 3 trials for four investigational candidates in hematologic malignancies and solid tumors, including bomedemstat, nemtabrutinib, MK-2870, and MK-5684. The trials demonstrate the company's commitment to research across novel mechanisms of action in various cancers, such as lung, endometrial, and prostate cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
clinical trial

FAQ

What is the current stock price of Merck & Co. (MRK)?

The current stock price of Merck & Co. (MRK) is $101.16 as of November 25, 2024.

What is the market cap of Merck & Co. (MRK)?

The market cap of Merck & Co. (MRK) is approximately 256.1B.

What are the main therapeutic areas Merck focuses on?

Merck focuses on several therapeutic areas including cardiometabolic diseases, cancer, and infections. They also have a significant vaccine business and an animal health division.

What is Merck for Mothers?

Merck for Mothers is Merck’s global initiative dedicated to improving maternal health. The program has reached over 30 million women with initiatives that promote safe, high-quality care during pregnancy and childbirth.

What are some of Merck’s key products in oncology?

Merck's oncology portfolio includes KEYTRUDA, an immunotherapy used to treat various cancers, including melanoma. KEYTRUDA has shown significant benefits when used in combination with other therapies.

How significant is Merck’s vaccine business?

Merck has a substantial vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their vaccines portfolio is a major contributor to their public health impact.

Where is Merck headquartered?

Merck is headquartered in Rahway, New Jersey, USA.

What percentage of Merck’s sales comes from the United States?

Approximately half of Merck's sales are generated in the United States.

What is Merck's approach to research and development?

Merck invests heavily in research and development with over 2,250 ongoing clinical trials. Their approach focuses on innovative treatments and combination regimens to address complex health challenges.

What recent achievements has Merck announced?

Merck recently surpassed its goal of reaching 25 million women with its maternal health initiative, Merck for Mothers, by reaching over 30 million women. Additionally, they have reported promising results from clinical trials involving KEYTRUDA.

Does Merck collaborate with other companies for research?

Yes, Merck is actively involved in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

What is the historical origin of Merck & Co., Inc.?

Merck & Co., Inc. originated from the Merck Group, which was founded in Germany in 1668. The American arm, now an independent company, was established to serve the United States and Canada.

Stock MRK logo
Merck & Co., Inc.

NYSE:MRK

MRK Rankings

#34 Ranked by Market Cap
#933 Ranked by Dividends

MRK Stock Data

256.11B
2.53B
0.06%
79.47%
1.04%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
KENILWORTH